Publication: Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score >= 50%: KEYNOTE-598.
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
LIPPINCOTT WILLIAMS & WILKINS